Date: July 27, 2026

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **BSE Scrip Code: 544319**	To, Sr. General Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051 **NSE Symbol: SENORES**

Sub.: Outcome of Board Meeting of the Company held on Monday, July 27, 2026

Dear Sir/Madam,

In compliance with Regulations 30, 33, and 47 read with Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Monday, July 27, 2026, has inter-alia, approved the following:

1. **Unaudited Financial Results of the Company**

   Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026, together with the Limited Review Report thereon;

   Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company hereby confirms and declares that M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Unaudited Consolidated and Standalone Financial Results of the Company for the quarter ended June 30, 2026.

   The financial results along with the reports of the auditors of the Company are enclosed herewith as **Annexure-A.**

   Media Release in relation to the Unaudited Consolidated and Standalone financial results of the Company for the quarter ended June 30, 2026, is enclosed herewith as **Annexure -B.**

2. **Change in the Senior Management Personnel ("SMP") of the Company**

   Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we wish to inform you that the Board, on recommendation of the Nomination and Remuneration Committee, approved the appointment and categorization of Ms. Anjali Shah, Assistant Vice President-Finance as Senior Management Personnel ("SMP") of the Company with effect from July 27, 2026.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the **Annexure-C**.

Kindly note that the meeting of Board of Directors of the Company commenced at 01:45 P.M. (IST) and concluded at 02:55 P.M. (IST).

This intimation and aforesaid information are also being uploaded on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

DEVAL RAJNIKANT SHAH Digitally signed by DEVAL RAJNIKANT SHAH Date: 2026.07.27 15:12:27 +05'30'

Deval Rajnikant Shah
Whole Time Director & CFO
DIN: 00332722

Enclosures: As above

Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah	CA. Chintan Shah	CA. Nilesh Shah	CA. Manali Shah	CA. Sandip Gupta
B.Com., F.C.A., Ph. D. (Commerce)	B.Com., L.L.B., F.C.A.	B.Com., L.L.B., F.C.A.	B.Com., F.C.A.	B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : http://www.prsca.in

Independent Auditors Limited Review Report on the Quarter ended Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, (the "Listing Regulations").

Review Report to,
The Board of Directors
Senores Pharmaceuticals Limited,

We have reviewed the consolidated statement of unaudited consolidated financial results of **Senores Pharmaceuticals Limited** (the "company") for the quarter ended on 30th June, 2026 (the "statement") including its subsidiary's share of net profit/ after tax and total comprehensive income/loss, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

The statement includes the results of the following entities;
Parent:
Senores Pharmaceuticals Limited

Subsidiary:

1. Senores Pharmaceuticals INC
2. Ratnatris Pharmaceuticals Private Limited
3. Havix Group INC
4. Apnar Pharma Private Limited

Step down Subsidiary:

1. 9488 Jackson Trail LLC
2. Zoraya Pharmaceuticals LLC
3. Amerisyn LLC

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The accompanying statements includes unaudited interim financial results of 4 subsidiaries and 3 Stepdown subsidiaries included in the statement, whose unaudited interim financial results reflect total revenues Rs.181.19 Crores, total net profit after tax of Rs. 31.22 Crores and total comprehensive income is Rs. 31.22 crores for the quarter ended 30th June, 2026 respectively, as considered in the respective consolidated unaudited financial results. These unaudited interim financial results of this subsidiary has been reviewed by their auditors and have been approved and furnished to us by the management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such unaudited interim financial results and information. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date:27-07-2026
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W

N. R. Shah

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

CA Nilesh Shah
Partner
Membership No.107414
UDIN: 26107414PGXPKX5989

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | **Website:** www.senorespharma.com | **Phone:** +91-79-29999857 | **E-mail:** cs@senorespharma.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30,2026

(Rs. in Crores)

Sr No.	Particulars	For Quarter ended			Year ended
		June 30 , 2026	March 31 , 2026	June 30 , 2025	March 31 , 2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations	180.21	175.19	132.56	632.63
2	Other Income	2.81	17.67	8.79	47.06
3	**Total Income**	**183.02**	**192.86**	**141.35**	**679.69**
4	**Expenses**				
	Cost of materials consumed	31.15	27.05	29.38	114.27
	Purchases of stock-in-trade	34.01	35.71	27.55	137.32
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.56	3.46	4.43	0.07
	Employee benefits expenses	29.91	30.32	21.65	112.25
	Finance costs	7.17	8.46	5.04	25.03
	Depreciation & Amortisation expenses	9.94	9.30	5.99	31.25
	Other expenses	30.82	31.16	20.81	100.40
	Total expenses	**143.56**	**145.46**	**114.86**	**520.59**
5	**Profit before Tax**	**39.46**	**47.40**	**26.49**	**159.10**
6	**Tax expense**				
	Current tax	9.82	(4.97)	4.91	19.94
	Deferred tax	(0.81)	15.70	0.40	17.63
	Total Tax Expense	**9.01**	**10.73**	**5.31**	**37.57**
7	**Net Profit after tax**	**30.45**	**36.67**	**21.18**	**121.53**
8	**Other Comprehensive Income / (Loss)**				
	A (i) Items that will not be reclassified subsequently to profit or loss	0.00	0.24	-	(0.02)
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	(0.08)	-	(0.01)
	B (i) Items that will be reclassified subsequently to profit or loss	0.51	41.76	0.47	29.22
	(ii) Income tax relating to items that will be reclassified to profit and loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	**0.51**	**41.92**	**0.47**	**29.19**
9	**Total Comprehensive Income**	**30.96**	**78.59**	**21.65**	**150.72**
10	**Profit for the period attributable to**				
	Equity Holders of the Company	30.72	31.61	19.73	115.38
	Non Controlling Interests	(0.27)	5.06	1.45	6.16
	Other Comprehensive Income attributable to				
	Equity Holders of the Company	0.48	36.95	0.32	26.96
	Non Controlling Interests	0.03	4.97	0.15	2.23
	Total Comprehensive Income attributable to				
	Equity Holders of the Company	31.20	68.56	20.05	142.34
	Non Controlling Interests	(0.24)	10.03	1.60	8.39
11	**Paid up Equity Share Capital (Face Value Rs 10 per share)**				46.05
12	**Other Equity**				887.55
13	**Earnings per share (in Rupees) (Face Value Rs 10 per share)**				
	(Not annualised for the quarter)				
	Basic	6.61	7.96	4.60	26.39
	Diluted	6.60	7.96	4.60	26.39

Senores Pharmaceuticals Limited Ahmedabad

For Senores Pharmaceuticals Limited

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Place : Ahmedabad
Date : July 27,2026

Notes to Consolidated Financial Results:

1. The unaudited consolidated financial results of Senores Pharmaceuticals Limited ("Company") for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on July 27, 2026. The Statutory auditors have carried out a limited review of the consolidated financial results of the Company for the quarter ended June 30, 2026.

2. The unaudited consolidated financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3. The figures for the last quarter ended March 31, 2026 are balancing figures between the audited figures in respect of the full year ending March 31, 2026 and the unaudited published year to date figures up to December 31, 2025, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

4. The unaudited consolidated financial results include the results of the following subsidiaries and step-down subsidiaries:

   i. Senores Pharmaceuticals Inc
   ii. Havix Group Inc
   iii. Ratnatris Pharmaceuticals Private Limited
   iv. Apnar Pharma Private Limited
   v. 9488 Jackson Trail LLC (Step-Down Subsidiary)
   vi. Zoraya Pharmaceuticals LLC (Step-Down Subsidiary)
   vii. Amerisyn, LLC (Step-Down Subsidiary)

5. Senores Pharmaceuticals Inc, wholly owned subsidiary of the Company, has entered into an Operating Agreement dated April 02, 2026 ("Agreement") to form a company named Amerisyn, LLC ("Amerisyn"). As per the terms of the Agreement SPI has subscribed to 70% of the membership interest in Amerisyn, which accordingly, has become a step-down subsidiary of the Company.

6. During the previous year, the Holding Company had acquired 75% equity stake in Apnar Pharma Private Limited ("Apnar") on 16th January, 2026 in accordance with the Share Purchase Agreement ("SPA") with its selling Shareholders. As per the SPA, the balance 25% equity stake in Apnar will be acquired post completion of due certain formalities as mentioned in the SPA. The consideration payable to the remaining selling shareholders is disclosed under the Financial Liabilities. The Company has made line by line consolidation of items of profit and loss and Balance sheet after Acquisition and has given effect of Goodwill arising out of this Acquisition as per IND AS 103 while preparing these consolidated unaudited financial results.

7. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.

Senores Pharmaceuticals Limited Ahmedabad

8. The Proceeds of IPO have been utilized till June 30, 2026 as per the below mentioned table:

(Rs in crores)

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on June 30, 2026	Amount utilized till June 30, 2026	Amount unutilized as on June 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility *(Refer Note 1)*	107.00	6.98	100.02	Out of the unutilized amount, Rs 100.44 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.10 crores held in HDFC bank account.
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company *(Refer Note 3)*	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes *(Refer Notes 2 & 3)*	161.91	161.63	0.28	
7	Offer expenses *(Refer Note 3)*	35.04	34.80	0.24	
	Total	**500.00**	**399.46**	**100.54**	

Note 1: The company has sought shareholders' approval through postal ballot for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit by curtailing the Object 1 to make investment in one of the subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in Atlanta Facility.

Note 2: During the quarter, Rs. 4.47 crores have been utilized towards General Corporate Purpose (GCP) for Object 6. Out of total utilized funds of Rs. 161.63 crores for Object 6, Rs. 69.80 crores is towards General Corporate Purpose (GCP) and Rs 91.83 is utilized towards other strategic initiatives till June 30, 2026.

Note 3:

i. Surplus portion of Rs. 0.38 crores on fulfillment of Object 2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated July 23, 2025.

ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated March 28, 2026.

iii. Out of the surplus portion of Offer expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14, 2026.

Senores Pharmaceuticals Limited Ahmedabad

9. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating Rs 95 crore at an issue price of Rs 812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received Rs 23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.

10. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.

11. The Group is operating in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.

12. Previous period figures have been regrouped and / or re-arranged wherever necessary to make their classification comparable with current period.

Senores Pharmaceuticals Limited Ahmedabad

For Senores Pharmaceuticals Limited

Place: Ahmedabad
Date: July 27, 2026

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Independent Auditors' Limited Review Report on Quarterly unaudited Standalone Ind AS Financial Results of M/s Senores Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,

The Board of Directors

Senores Pharmaceuticals Limited

Report on audit of Standalone Ind AS Financial Results

We have reviewed the accompanying Statement of Standalone Ind AS Financial Results of Senores Pharmaceuticals Limited (the "Company"), for the quarter ended June 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

Tax Provision and Deferred Tax has been determined as estimated by the management. Our conclusion on the statement is not modified in the respect of these matters.

For Pankaj R Shah & Associates
Chartered Accountants
(Firm Regn.No.107361W)

PANKAJ R. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS AHMEDABAD

N. R. Shah

CA Nilesh Shah
Partner
Membership No. 107414
UDIN : 26107414MZQHHM5298
Place: Ahmedabad
Date: 27-07-2026

SENORES PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | **Website:** www.senorespharma.com | **Phone:** +91-79-29999857 | **E-mail:** cs@senorespharma.com

Statement of Unaudited Standalone Financial Results for the Quarter ended June 30,2026

(Rs. in Crores)

Sr No.	Particulars	For Quarter ended			Year ended
		June 30 , 2026	March 31 , 2026	June 30 , 2025	March 31 , 2026
		Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations	26.99	36.81	16.13	106.09
2	Other Income	9.55	22.19	12.08	66.35
3	**Total Income**	**36.54**	**59.00**	**28.21**	**172.44**
4	**Expenses**				
	Cost of materials consumed	7.47	18.36	1.40	24.55
	Purchases of stock-in-trade	4.19	5.10	2.34	30.42
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.49	0.06	3.41	(0.30)
	Employee benefits expenses	10.10	11.12	6.91	38.78
	Finance costs	2.22	1.89	1.76	6.98
	Depreciation & Amortisation expenses	3.61	4.13	1.88	13.23
	Other expenses	7.07	5.65	6.92	31.32
	Total expenses	**35.15**	**46.31**	**24.62**	**144.98**
5	**Profit before Tax**	**1.39**	**12.69**	**3.59**	**27.46**
6	**Tax expense**				
	Current tax	0.31	6.48	0.39	8.45
	Deferred tax	0.05	(2.27)	0.51	(1.24)
	Total Tax Expense	**0.36**	**4.21**	**0.90**	**7.21**
7	**Net Profit after tax**	**1.03**	**8.48**	**2.70**	**20.25**
8	**Other Comprehensive Income / (Loss)**				
	A (i) Items that will be reclassified to profit or loss	0.00	0.09	-	(0.01)
	(ii) Income tax relating to items that will be reclassified to profit and loss	(0.00)	(0.03)	-	0.00
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	**0.00**	**0.06**	**-**	**(0.01)**
9	**Total Comprehensive Income**	**1.03**	**8.54**	**2.70**	**20.24**
10	**Paid up Equity Share Capital (Face Value Rs 10 per share)**				46.05
11	**Other Equity**				703.85
12	**Earnings per share (in Rupees) (Face Value Rs 10 per share)** ***(Not annualised for the quarter)***				
	Basic	0.22	1.84	0.59	4.40
	Diluted	0.22	1.84	0.59	4.40

For Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited Ahmedabad

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Place : Ahmedabad
Date : July 27,2026

Notes to Standalone Financial Results:

1. The standalone unaudited financial results of Senores Pharmaceuticals Limited ("Company") for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meetings held on July 27, 2026. The Statutory auditors have carried out a limited review of the standalone financial results of the Company for the quarter ended June 30, 2026.

2. The standalone unaudited financial results of Senores Pharmaceuticals Limited have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

3. The figures for the last quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full year ending March 31, 2026 and the unaudited published year-to-date figures up to December 31, 2025, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

4. The Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.

5. The Proceeds of IPO have been utilized till June 30, 2026 as per the below mentioned table:

Sr. No	Item Head	Amount as proposed in the Offer Document and as Revised as on June 30, 2026	Amount utilized till June 30, 2026	Amount unutilized as on June 30, 2026	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility (Refer Note 1)	107.00	6.98	100.02	Out of the unutilized amount, Rs 100.44 crores parked as Fixed Deposit with ICICI Bank and the balance Rs. 0.10 crores held in HDFC bank account.
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company *(Refer Note 3)*	73.10	73.10	0.00	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.20	20.20	0.00	
4	Funding the working capital requirements of our Company	43.26	43.26	0.00	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	59.48	0.00	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes *(Refer Notes 2 & 3)*	161.91	161.63	0.28	
7	Offer expenses *(Refer Note 3)*	35.04	34.80	0.24	
	Total	**500.00**	**399.46**	**100.54**	

Senores Pharmaceuticals Limited Ahmedabad

Note 1: The company has sought shareholders' approval through postal ballot for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit by curtailing Object 1 to make investment in one of the subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in Atlanta Facility.

Note 2: During the quarter, Rs. 4.47 crores have been utilized towards General Corporate Purpose (GCP) for Object 6. Out of total utilized funds of Rs. 161.63 crores for Object 6, Rs. 69.80 crores is towards General Corporate Purpose (GCP) and Rs 91.83 is utilized towards other strategic initiatives till June 30, 2026.

Note 3:

i. Surplus portion of Rs. 0.38 crores on fulfillment of Object-2 & Rs. 0.02 crores on fulfillment of Object-3 are transferred to Object-6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated July 23, 2025.

ii. Surplus portion of Rs. 6.31 crores of Object 7 have been transferred to Object 6 (General Corporate Purpose ("GCP") as approved by the Board in its meeting dated March 28, 2026.

iii. Out of the surplus portion of Offer Expenses Rs.0.84 crore is transferred to the object of Funding inorganic growth through acquisition and other strategic initiatives and General Corporate Purpose (GCP) as approved in the board meeting dated May 14,2026.

7. The Board of Directors, at its meeting held on March 28, 2026, allotted 11,70,000 warrants to the Promoter and Promoter Group on a preferential basis, aggregating ₹95 crore at an issue price of ₹812 per warrant, pursuant to the shareholders' approval received on January 31, 2026. Each warrant is convertible into one equity share within 18 months from the date of allotment. During the year ended March 31, 2026, the Company received ₹23.75 crore, representing the minimum upfront subscription amount of 25% of the issue price.

8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.

9. The Company operates in a single segment i.e. Pharmaceuticals. Hence, the above financial results are based on a single segment only.

10. Previous period figures have been regrouped and/or rearranged, wherever necessary to make their classification comparable with current period.

Senores Pharmaceuticals Limited
Ahmedabad

For Senores Pharmaceuticals Limited

Place: Ahmedabad
Date: July 27, 2026

Swapnil Jatinbhai Shah
Managing Director
DIN: 05259821

Senores
Committed to Global Wellness!

SENORES PHARMACEUTICALS LIMITED

Strong Financial & Operational Performance for Q1 FY27

Ahmedabad, Gujarat, 27th July 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited Financial Result for the quarter ended 30th June 2026.

Q1 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue	EBITDA	PAT
₹ 180 crs	₹ 54 crs	₹ 31 crs
+36% *Y-o-Y*	+87% *Y-o-Y*	+56% *Y-o-Y*

Q1 FY27 SEGMENTAL HIGHLIGHTS

Segment Revenue (₹ crs)	Q1FY27	Q1FY26	*Y-o-Y*
Regulated Markets	127.8	90.1	*41.9%*
Emerging Markets	37.6	29.0	*29.6%*
Branded Generics	8.0	8.2	*-2.4%*
Others	6.8	5.2	*29.2%*
Total Revenue	**180.2**	**132.6**	***35.9%***

Senores
Committed to Global Wellness!

Q1 FY27 FINANCIAL & BUSINESS HIGHLIGHTS

✓ Consistently strong and broad based growth across businesses

- Consistently delivering robust performance with Revenue for Q1FY27 growing **by 36% Y-o-Y.**
- Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of **42% & 30% respectively** on a Y-o-Y basis.

✓ Robust improvement in profitability

- EBIDTA for Q1FY27 grew by 87% with margin expansion of ~800 bps on a Y-o-Y basis.
- Steady focus on manufacturing & cost efficiency enabling sustainable margin growth & expansion

✓ Continued expansion of product portfolio

- Nearly doubled our Regulated Markets portfolio, expanding from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026, out of which 23 ANDAs have been commercialized.

✓ Emerging Markets on Steady Trajectory

- Emerging Markets business on a steady growth trajectory. Revenue growing by ~30% Y-o-Y in Q1 FY27. EBITDA Margin stood at approximately 14%, Supported by an increasing focus on niche products and streamlined go-to-market strategies.

✓ Outlook remains extremely positive

- With a strong foundation, differentiated product portfolio, and a clearly defined roadmap, we are well positioned to sustain our growth momentum and deliver another year of strong performance in FY27 and beyond.
- Based on the current business outlook and execution visibility, we expect strong revenue growth & expanding profitability for FY27. This confidence is underpinned by a robust product pipeline, with strong visibility of commercial launches over the coming quarters.

Commenting on the performance, ***Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited*** *said,*

"Building on the strong momentum from the previous year and driven by our well-defined strategic priorities, we delivered a healthy performance in the first quarter of FY27 despite a challenging operating environment.

Our Regulated Markets business delivered strong performance in Q1FY27, registering a robust 42% year-over-year revenue growth. This was driven by the continuous expansion of our product portfolio and differentiated sales & distribution channels. Through a balanced blend of in-house development and targeted acquisitions, we have strategically strengthened our ANDA portfolio.

The Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now near mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive.

The addition of Baroda-based USFDA approved manufacturing plant enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO & CMO opportunities, positioning Senores for sustained growth. Production is already ramped up at Apnar facility, with full scale-up and further expansion is expected over the next 12–18 months.

Our specific purpose marketing and distribution subsidiaries are expected to scale up significantly over the next few years and will structurally advance our entire U.S. business to multifold.

All in all, we have continued to deliver on our stated commitments through disciplined execution, operational excellence, and a relentless focus on growth. Our ability to consistently execute across functions while maintaining financial discipline reflects the resilience of our business model, the credibility of our long-term strategy, and the execution-driven culture that is deeply embedded across Senores. We remain confident in sustaining this momentum in the years ahead, led by robust product pipeline, expanded manufacturing capacities, and a strengthened R&D infrastructure."

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 58 ANDAs and 16 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 513 product registrations and 942 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, second in Gujarat, which is also US-FDA approved and the third in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to Emerging Markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

For more information, please contact

Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899

Senores
Committed to Global Wellness!

Annexure-C

Details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr. No	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Ms. Anjali Shah, Assistant Vice President-Finance, categorized as SMP of the Company with effect from July 27, 2026.
2.	Date of appointment/re-appointment/cessation (as applicable) and term of appointment	Effective from July 27, 2026 Terms and conditions as mentioned in the letter of appointment.
3	Brief Profile (in case of appointment)	Ms. Anjali Shah is a qualified Chartered Accountant from the Institute of Chartered Accountants of India (ICAI) and holds a Bachelor of Commerce degree. She has a strong academic foundation in finance, accounting, taxation, and corporate laws. She brings over 10 years of diverse experience across finance, taxation, treasury, financial reporting, consolidation, regulatory compliance, internal controls, and cross-border financial management. She has successfully led finance functions across domestic and international entities, with significant exposure to IPOs, investor reporting, cash flow management, and stakeholder engagement. Prior to joining the Company, Ms. Shah served as Chief Financial Officer at Remus Pharmaceuticals Ltd. and held other dynamic roles, where she has helped organizations strengthen financial controls, optimize business processes, and support strategic initiatives focussed on long-term value creation.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Senores Pharmaceuticals Limited
1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263